XIE Yanhua, CHEN Jie. Effects of Zhipo Liujunzi Decoction combined with sequential treatment on T lymphocyte subsets in patients with middle or advanced stage gastric cancer[J]. Journal of Clinical Medicine in Practice, 2020, 24(8): 47-50. DOI: 10.7619/jcmp.202008012
Citation: XIE Yanhua, CHEN Jie. Effects of Zhipo Liujunzi Decoction combined with sequential treatment on T lymphocyte subsets in patients with middle or advanced stage gastric cancer[J]. Journal of Clinical Medicine in Practice, 2020, 24(8): 47-50. DOI: 10.7619/jcmp.202008012

Effects of Zhipo Liujunzi Decoction combined with sequential treatment on T lymphocyte subsets in patients with middle or advanced stage gastric cancer

More Information
  • Received Date: February 04, 2020
  • Objective To analyze effects of Zhipo Liujunzi Decoction combined with sequential treatment on T lymphocyte subsets in patients with middle or advanced stage gastric cancer. Methods A total of 112 patients with middle or advanced gastric cancer hospitalized in our hospital were selected, and were divided into control group(n=56)and study group(n=56)according to random number table method. The control group was given sequential treatment, while the control group was treated with Zhipo Liujunzi Decoction combined with sequential treatment, and the clinical efficacy, serum tumor markers, T lymphocyte subgroup factors, and incidence of toxic and side effects were compared between the two groups. Results The total clinical effective rate in the experimental group was significantly higher than that in the control group(89.29% vs. 64.29%, P<0.05). After 3 courses of treatment, the levels of CD3+, CD4+, and CD4+ /CD8+ in the experimental group were significantly higher than those of the control group(P<0.05). The incidence of toxic side effects in the experimental group was significantly lower than the control group(P<0.05). The levels of serum carbohydrate antigen-724(CA-724), carcinoembryonic antigen(CEA), carbohydrate antigen-199(CA-199)in the experimental group were significantly lower than that of the control group after 3 courses of treatment(P<0.05). Conclusion Zhipo Liujunzi Decoction combined with sequential treatment can effectively inhibit the growth of tumor lesions, improve immune function, suppress serum tumor markers, and reduce the incidence of toxic and side effects in patients with middle or advanced stage gastric cancer.
  • 邓峰, 张茹虎, 朱磊. 奥沙利铂联合卡培他滨对中晚期胃癌患者术后化疗的疗效及对血清CA125、CEA、TPS、CYFRA21-1、CA19-9及T淋巴细胞亚群水平的影响[J]. 海南医学院学报, 2016, 22(17): 2011-2014

    , 2018.
    王森. 扶正抗癌方联合自体CIK免疫治疗对中晚期胃癌患者细胞免疫功能和远期生存率的影响[J]. 现代中西医结合杂志, 2016, 25(27): 2979-2981

    , 2984.
    李玮, 赵鹏. 多西他赛+奥沙利铂+替吉奥与多西他赛+顺铂+氟尿嘧啶方案治疗晚期胃癌的对比研究[J]. 海南医学院学报, 2016, 22(17): 2015-2018.
    陈宓, 贾霖, 苏州. 艾迪联合DP方案治疗Ⅳ期胃癌患者的疗效及对其免疫功能的影响分析[J]. 广西医科大学学报, 2016, 33(3): 519-521.
    Hong J, Chen X S, Huang J H, et al. Danggui buxue decoction, a classical For Mula of traditional Chinese medicine, fails to prevent myelosuppression in breast cancer patients treated with adjuvant chemotherapy: a prospective study[J]. Integr Cancer Ther, 2017, 16(3): 406-413.
    宋仲洁. 替吉奥联合奥沙利铂化疗方案治疗老年晚期胃癌的临床研究[J]. 癌症进展, 2016, 14(2): 162-164.
    祝利民, 郭玲建, 毛竹君, 等. 健脾益肾解毒方联合化疗对中晚期胃癌患者癌因性疲乏及免疫功能的影响[J]. 微循环学杂志, 2019, 29(3): 39-44

    , 48.
    卢宏霞, 杨牡丹, 高峻, 等. 脾多肽注射液联合FLOT方案治疗晚期胃癌的效果及对患者免疫功能的影响[J]. 肿瘤研究与临床, 2019, 31(2): 121-124.
    郭元彪, 应海峰, 郑岚, 等. 健脾克癌宁联合四君子汤加减治疗脾气虚型胃癌术后患者疗效及对机体免疫功能的影响[J]. 现代中西医结合杂志, 2017, 26(12): 1280-1282

    , 1286.
    Tanizawa Y, Bando E, Tokunaga M, et al. 59. Efficacy of surgical treatment for responders to chemotherapy for gastric cancer with Para-aortic lymph node metastasis[J]. Eur J Surg Oncol EJSO, 2016, 42(9): S89-S90.
    李海, 游红勇, 陈智敏, 等. 腹腔镜辅助胃癌D2端根治术治疗胃癌合并2型糖尿病的效果及其对炎症因子和免疫功能的影响[J]. 中国医药导报, 2016, 13(11): 100-103.
    孙源. 肠内营养联合大柴胡汤加味对胃癌术后早期免疫功能及胃肠功能的影响[J]. 现代中西医结合杂志, 2017, 26(24): 2646-2648

    , 2684.
    王玉梅, 刘博, 张莉, 等. 十全大补汤联合肠内营养支持对老年胃癌术后气血两虚证病人营养状况和免疫功能的影响[J]. 安徽医药, 2019, 23(11): 2270-2274.
    郭蓉, 赫晓磊, 高峰. 血清超敏C反应蛋白、癌胚抗原、糖类抗原724和糖类抗原199检测对胃癌及其相关病变的早期诊断价值[J]. 安徽医药, 2019, 23(1): 106-109.
    Iizumi S, Takashima A, Narita Y, et al. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study[J]. Cancer Chemother Pharmacol, 2017, 80(3): 575-582.
  • Related Articles

    [1]SHI Qianqian, LIU Jingjing. Risk factor and construction of nomogram prediction model for pertussis in children[J]. Journal of Clinical Medicine in Practice, 2025, 29(6): 56-61. DOI: 10.7619/jcmp.20244333
    [2]WANG Wang, ZHAO Han. Construction of a nomogram prediction model for catheter-related bloodstream infections in hemodialysis patients with chronic renal failure[J]. Journal of Clinical Medicine in Practice, 2024, 28(18): 95-100. DOI: 10.7619/jcmp.20240464
    [3]ZHU Huayuan, ZHANG Yajuan, SUN Qian, HUANG Yan, YANG Bingyin. Establishment of a Nomogram prediction model for chronic constipation patients based on body position exercise training[J]. Journal of Clinical Medicine in Practice, 2024, 28(17): 109-113. DOI: 10.7619/jcmp.20241488
    [4]CHEN Chunmei, ZHANG Rong, CHU Jie, WANG Xuexing. Influencing factors of malnutrition in patients with colorectal cancer and value of Nomogram prediction model[J]. Journal of Clinical Medicine in Practice, 2024, 28(17): 20-26. DOI: 10.7619/jcmp.20241893
    [5]REN Weiwei, WANG Chao, MENG Junhua, XU Suhong. Establishment and validation of an individualized risk prediction nomogram model for gestational diabetes mellitus in pregnant women with hypothyroidism[J]. Journal of Clinical Medicine in Practice, 2024, 28(16): 93-97. DOI: 10.7619/jcmp.20234265
    [6]WU Xueqin, JIN Rong, CAO Xia. Construction of nomogram model for predicting risk of maternal postpartum chronic low back pain[J]. Journal of Clinical Medicine in Practice, 2023, 27(16): 121-126. DOI: 10.7619/jcmp.20231835
    [7]ZHU Ting, ZHOU Hailan, HUA Xiaofan. Establishment and application of Nomogram model for prediction of recurrence after breast cancer surgery based on multi-dimensional indicators[J]. Journal of Clinical Medicine in Practice, 2023, 27(5): 43-48. DOI: 10.7619/jcmp.20221838
    [8]DONG Yanping, WANG Jiemin, WANG Yujin, REN Yali, DONG Yucheng, YONG Yanjun, SU Xuandi, WANG Jixiang, SU Nan, WANG Fuli, XIA Duosheng. Construction and evaluation of Nomogram prediction model for postoperative recurrence of pterygium[J]. Journal of Clinical Medicine in Practice, 2022, 26(7): 52-56. DOI: 10.7619/jcmp.20214610
    [9]HU Tingting, GUO Qiu, TANG Weiwei, YANG Huan, LIU Guijun. A Nomogram model establishment for noscomial infection in elderly patients with hypertension and diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 55-60. DOI: 10.7619/jcmp.20210055
    [10]ZHANG Zhen, ZHANG Hengzhu, LI Yuping, YAN Zhengcun, DONG Lun, WANG Xiaodong, WANG Xingdong. Relationship between systemic inflammation response index and symptomatic cerebral vasospasm after aneurismal subarachnoid hemorrhage as well as construction of a Nomogram predictive model[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 36-40. DOI: 10.7619/jcmp.202010009
  • Cited by

    Periodical cited type(10)

    1. 徐颖. 多层螺旋CT联合核磁共振成像增强扫描在胰腺癌及慢性胰腺炎鉴别诊断中的价值分析. 大医生. 2024(01): 127-129 .
    2. 高成强,毕司星,李立新. CT平扫联合增强扫描在胰腺癌诊断中的应用价值. 影像研究与医学应用. 2024(02): 31-33 .
    3. 侯胜楠. CT、MRI增强扫描对胰腺癌与慢性胰腺炎的鉴别诊断价值. 中华养生保健. 2024(07): 176-180 .
    4. 柳群力,朱鸷翔. CT联合分泌型卷曲受体蛋白4及可溶性生长刺激表达基因2蛋白对恶性胆道梗阻患者术后并发胰腺炎的诊断价值. 实用临床医药杂志. 2024(05): 59-62+67 . 本站查看
    5. 郑北. 联合应用CT、MRI增强扫描鉴别诊断胰腺癌与慢性胰腺炎的价值. 中国医疗器械信息. 2024(08): 12-14+25 .
    6. 曹中立. 多层螺旋CT在胰腺癌术前评估及诊断中的应用价值. 影像研究与医学应用. 2024(10): 132-134 .
    7. 杨懿,黄新蓉. MRI与CT检查诊断急性胰腺炎的价值比较研究. 影像研究与医学应用. 2024(14): 135-137+140 .
    8. 董源涛,尚金红,袁燕丽. MRI联合CT在胰腺肿瘤中的诊断价值. 影像研究与医学应用. 2024(16): 137-139 .
    9. 游红莲,闫明艳,褚千琨,王芳芳,陈文晶,于根建,王静. 隐匿性小胰腺癌并急性胰腺炎与单纯性急性胰腺炎的CT对比分析. 临床误诊误治. 2024(17): 63-68 .
    10. 刘强. 多层螺旋CT与MRI扫描鉴别诊断胰腺癌和胰腺炎的有效性探讨. 影像研究与医学应用. 2024(19): 24-26 .

    Other cited types(1)

Catalog

    Article views PDF downloads Cited by(11)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return